Global Perspectives

The excipient supplier's cGMP practices have been certified as meeting EXCiPACT standards

China’s emergence as a significant commercial market is forcing manufacturers to re-evaluate their overall business model.

With the Indian pharmaceutical industry on the rise, manufacturing businesses are working together with European and American partners to harness their longstanding experience and reputation in cleanroom manufacturing for a broader pharmaceutical manufacturing marketplace.

Hope abounds for local drug discovery companies despite challenges at home.

A new technical report guides bio/pharma companies in establishing a risk-based approach for prevention and management of drug shortages.

Changes in the country’s political landscape may affect the pharmaceutical industry market in the future.

Bio/pharmaceutical manufacturers in the UK face challenges in proving that their drugs are worth the price.

In late 2014, standards organizations continued to work towards harmonization and securing drug safety.

Enhanced R&D efforts and the growing manufacture of finished-dosage drugs in India will shape the country's future success, according to a new report from CPhI.

The spate of drug scandals may alter the relationship between manufacturers and research institutions, and reshape Japan’s clinical research industry.

Approximately 40% of total global growth will come from specialty medications, according to a new report from the IMS Institute for Healthcare Informatics.

The authors take a look at some of the recent developments in the German pharmaceutical market.

Chinese healthcare reforms may be a double-edged sword for foreign companies.

Is there potential for growth in Brazil's phytotherapic drug market?

Brunei harnesses its rich biodiversity and the growing halal market in a bid to develop its pharmaceutical sector.

To gain insights into the current trends of the biotechnology sector in the United Kingdom, Pharmaceutical Technology Europe spoke with Steve Bates, chief executive officer of the BioIndustry Association (BIA), the trade association for biotech companies in the UK.

China's regulatory and compliance environment is set to change as the government declares a crackdown on bribery scandals.

Last year, the Turkish Government unveiled plans to position the country in the top 10 most-preferred locations for R&D investment in the pharmaceutical sector by 2023. This article provides an overview of the incentives introduced under the Technopolis Law and the R&D Act.

Brazil is the first Latin American country to emerge as a global biopharmaceutical collaborator.

Israel's diverse population, high-quality healthcare system, and resilience to global financial stress make it a strong partner for R&D, clinical research, and market growth.

Ireland?s life-sciences sector has grown significantly since the 1960s. To gain insights into the competitive edge that Ireland offers to the pharmaceutical industry, Pharmaceutical Technology Europe spoke with Barry Heavey from IDA Ireland, which is a government agency responsible for attracting pharmaceutical and biotech companies to Ireland.

The pharmaceutical industry grows despite conflict in the Middle East.

Foreign companies zero in on Myanmar with the hope of securing a foothold in its pharmaceutical market.

Pharma eyes biologics production in Brazil as the government begins to recognize the potential of these drugs.

The bio-pharmaceutical business outlook in South Korea remains positive.

Brazil offers opportunities and challenges for global pharmaceutical companies.

A unique demographic and payer mix make ASEAN an increasingly attractive region.

The Taiwanese government engages in regulatory science in a move to boost its pharmaceutical sector.

Prior to price escalation of pharmaceutical products in Brazil, the country's regulatory authority released a study on price-cap control and its benefits in the past years.

Latin America's diverse growing market seeks regulatory harmonization.